| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 1g | |||
| Other Sizes |
| Targets |
Erlotinib D6 HCl targets the epidermal growth factor receptor (EGFR), an enzyme that plays a critical role in cell proliferation and survival. Erlotinib inhibits purified EGFR kinase with an IC₅₀ of 2 nM. It is 1000-fold more sensitive for EGFR than human c-Src or v-Abl.
|
|---|---|
| ln Vitro |
Erlotinib D6 HCl is primarily used as an analytical internal standard rather than for its pharmacological activity. Erlotinib is a quinazoline derivative with potent antineoplastic properties. It has been approved for the treatment of non-small cell lung cancer (NSCLC), pancreatic cancer and several other types of cancer.
|
| ln Vivo |
Erlotinib D6 HCl is used in pharmacokinetic studies as an internal standard for the quantification of Erlotinib. Erlotinib is an EGFR inhibitor approved for the treatment of NSCLC and pancreatic cancer. The deuterium-labeled compound can be co-administered with unlabeled drug to study absorption, distribution, metabolism, and excretion. It is used in bioequivalence studies and method validation.
|
| Enzyme Assay |
In vitro enzyme assays for Erlotinib D6 HCl are typically performed as part of analytical method validation. The compound is used as an internal standard in LC-MS/MS assays for the quantification of Erlotinib. It is dissolved in an appropriate solvent and spiked into biological matrices at known concentrations. Calibration curves are generated by plotting the peak area ratio of Erlotinib to Erlotinib D6 HCl against the concentration of Erlotinib.
|
| Cell Assay |
For in vitro cell-based assays, Erlotinib D6 HCl can be used in studies investigating Erlotinib's cellular effects, though its primary use is as an analytical internal standard. Cancer cell lines are cultured and treated with the compound. EGFR inhibition is confirmed by measuring the phosphorylation of downstream signaling proteins via Western blot. Cell viability is assessed by MTT or CellTiter-Glo assays.
|
| Animal Protocol |
In vivo animal studies with Erlotinib D6 HCl are primarily pharmacokinetic. The compound is administered orally to rodents, and blood samples are collected at predetermined time points. Plasma concentrations of both labeled and unlabeled Erlotinib are analyzed by LC-MS/MS using Erlotinib D6 HCl as the internal standard. Pharmacodynamic effects can be evaluated in xenograft models.
|
| ADME/Pharmacokinetics |
Erlotinib D6 HCl (CAS: 1189953-78-3) has a molecular weight of 435.93 g/mol and a molecular formula of C₂₂H₁₈D₆ClN₃O₄. Appearance: White to off-white solid powder. LogP: 4.28. Storage: Powder -20°C 3 years, 4°C 2 years; In solvent -80°C 6 months, -20°C 1 month.
|
| Toxicity/Toxicokinetics |
As a deuterium-labeled analog of an approved drug, Erlotinib D6 HCl is expected to have a similar toxicity profile to Erlotinib, though toxicity studies are typically not performed on the labeled compound. Erlotinib is generally well-tolerated, with common side effects including rash and diarrhea. The compound is used in very small quantities as an analytical internal standard and does not pose significant toxicity risks under normal handling.
|
| References | |
| Additional Infomation |
Erlotinib D6 HCl (CP358774 D6; NSC718781 D6; OSI774 D6) is a deuterated form of Erlotinib (CP-358774). Erlotinib is an EGFR inhibitor with an IC₅₀ of 2 nM and has been approved for the treatment of non-small cell lung cancer (NSCLC), pancreatic cancer and several other types of cancer. The labeled compound is intended for use as an internal standard and is not for therapeutic use.
|
| Molecular Formula |
C₂₂H₁₈D₆CLN₃O₄
|
|---|---|
| Molecular Weight |
435.93
|
| Exact Mass |
435.183
|
| CAS # |
1189953-78-3
|
| Related CAS # |
Erlotinib Hydrochloride;183319-69-9;Erlotinib-d6;1034651-23-4
|
| PubChem CID |
46781490
|
| Appearance |
White to off-white solid powder
|
| LogP |
4.28
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
30
|
| Complexity |
525
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[2H]C([2H])([2H])OCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC([2H])([2H])[2H].Cl
|
| InChi Key |
GTTBEUCJPZQMDZ-HVTBMTIBSA-N
|
| InChi Code |
InChI=1S/C22H23N3O4.ClH/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22;/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25);1H/i2D3,3D3;
|
| Chemical Name |
N-(3-ethynylphenyl)-6,7-bis[2-(trideuteriomethoxy)ethoxy]quinazolin-4-amine;hydrochloride
|
| Synonyms |
CP-358774 D6 HCl NSC-718781 D6NSC 718781CP-358,774 CP-358774 OSI-774 OSI 774 OSI774；OSI-774 D6CP358774,
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2939 mL | 11.4697 mL | 22.9395 mL | |
| 5 mM | 0.4588 mL | 2.2939 mL | 4.5879 mL | |
| 10 mM | 0.2294 mL | 1.1470 mL | 2.2939 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
